Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to determine the efficacy of 2 treatment regimens of daratumumab, as measured by the overall response rate (ORR) (complete response [CR] + partial response [PR]), in subjects with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD.
Critère d'inclusion
- Multiple myeloma